Inventiva (IVA) catalysts

Upcoming FDA decisions and readouts we track for Inventiva, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 07 Oct 2026

FreeBioList tracks 1 upcoming catalyst for Inventiva (IVA, listed on Nasdaq). It concerns Lanifibranor (MASH with F2/F3 fibrosis).

First on the list: the Phase 3 readout for Lanifibranor (MASH with F2/F3 fibrosis), guided by the company to Q4 2026.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 07 Oct 2026. The methodology page explains each status.

Background reading: How to read a Phase 3 topline readout.

Ticker: IVA
Next catalyst: Q4 2026
Type: Phase 3 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Inventiva IVA · Nasdaq	Lanifibranor	MASH with F2/F3 fibrosis	Q4 2026 company guidance	Phase 3 readout	Verified	6-K exhibit 99.3 ↗	Yes
Notes — Investor presentation lists "Q4 2026 NATiV3 TOPLINE" and "NATiV3 Topline Phase 3 results in F2/F3 MASH" as the first milestone. It notes timelines are "targets ... not committed". Source: 6-K exhibit 99.3, filed 28 Sep 2026 · verified 07 Oct 2026

Also due in Q4 2026

EyePoint (EYPT)Phase 3 readout for DURAVYU (vorolanib insert), Q4 2026
Invivyd (IVVD)Phase 3 readout for VYD2311, Oct 2026
Ocular Therapeutix (OCUL)Phase 3 readout for AXPAXLI (OTX-TKI), Q4 2026
Kodiak Sciences (KOD)Phase 3 readout for KSI-101, Dec 2026
Alumis (ALMS)Phase 3 readout for Envudeucitinib, Q4 2026
Savara Inc. (SVRA)PDUFA date for Molgramostim, 22 Nov 2026